EcoDrugPlus

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSEEEG00000003845
Gene Symbol: BCR
4 Cross references
209 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSEEEG00000014943
Gene Symbol: BTK
4 Cross references
204 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSEEEG00000007500
Gene Symbol: CXCR1
4 Cross references
275 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSEEEG00000021552
Gene Symbol: CFTR
2 Cross references
217 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSEEEG00000019242
Gene Symbol: DNMT1
4 Cross references
212 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSEEEG00000021118
Gene Symbol: TOP2A
2 Cross references
207 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSEEEG00000022197
Gene Symbol: TOP2B
4 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ia

Ensembl ID : ENSEEEG00000010752
Gene Symbol: TOP1A
4 Cross references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSEEEG00000010769
Gene Symbol: EML4
2 Cross references
212 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSEEEG00000012111
Gene Symbol: EPHA3
4 Cross references
216 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSEEEG00000006434
Gene Symbol: F2RL3
4 Cross references
191 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion A

Ensembl ID : ENSEEEG00000012154
Gene Symbol: FAUA
4 Cross references
300 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).